Page 106 - Aet News Today

Traditionally offering family building support, Progyny is expanding into the menopause space. Employees of its employer customers will receive a personalized care plan that includes support for nutrition, sleep, mental health and hormonal health — all factors that affect menopause.

In the future, research in personalized nutrition needs to focus on understanding the role of nutrition throughout the entire lifespan and address diet-related conditions through comprehensive interventions that go beyond simply choosing healthy foods.

Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.

“Botched math” in calculating clinical data for an autoimmune disease drug is one of the allegations Nektar Therapeutics makes in a legal complaint against Eli Lilly. The biotech claims its former partner tried to disadvantage the asset in order to advance development of another drug it acquired in a billion dollar deal.

HHS issued an alert warning providers about Rhysida, a ransomware gang that recently begun launching attacks on healthcare organizations. The group deploys its ransomware primarily through phishing attacks or the exploitation of legitimate cybersecurity tools.

About 27% of Medicare Advantage enrollees are Black, Latino or Asian, versus 17% of traditional Medicare enrollees, according to a report conducted by ATI Advisory and commissioned by the Better Medicare Alliance.

Peter Long of Blue Shield of California discusses how they focus on member experience and ways to improve their overall healthcare needs.

Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.

HCA and Tenet reported net incomes for the second quarter, while CHS posted a net loss. All three health systems found themselves in a better financial position in Q2 2023 than they were in Q2 of last year, driven in large part by declining contract labor expenses.

Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder. Vistagen’s stock price rocketed skyward on the results, which support progression to another Phase 3 study.